ÂÜÀòÂÒÂ×

José M. Mejía Oneto is the founder and CEO of Shasqi. José was previously a Denny and Jeanene Dickenson Fellow at UC Davis Medical Center from June 2010 to June 2014, during which time they worked on the Covalent Targeting Project.

The problem that Mejía Oneto isolated was the need for better drug delivery with fewer side effects. José conceived of a potential solution and designed an approach to test it. José submitted a record of invention and worked closely with the Technology Transfer office to convince stakeholders to support the project. Mejía Oneto raised intramural and extramural funding, designed and outsourced chemical synthesis, and determined the modalities needed to test their idea.

José established collaborations with research groups with experience in the required modalities and developed the necessary skills in diverse modalities, including radiochemistry, HPLC, animal studies, in-vivo animal imaging (SPECT-CT), and biodistribution studies. José created new assays to assess the efficiency of reactions with biomaterials and presented their work to multi-disciplinary audiences. Mejía Oneto worked closely with physicians, engineers, scientists, technicians, students, and other employees from different backgrounds to establish coast-to-coast collaborations. José submitted a provisional patent for their work through the Technology Transfer office and submitted their work for publication.

José M. Mejía Oneto has a MD from the University of Minnesota Medical School, a PhD in Chemistry from Emory University, and a Bachelor of Arts in Chemistry & Biology from Macalester College.

A direct report to José M. Mejía Oneto is and Sebastian Sanchez De Lozada - CFO.